The trading price of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) closed higher on Tuesday, October 12, closing at $14.71, 2.01% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $14.40 and $14.995. In examining the 52-week price action we see that the stock hit a 52-week high of $18.48 and a 52-week low of $3.46. Over the past month, the stock has lost -5.04% in value.
BioCryst Pharmaceuticals Inc., whose market valuation is $2.54 billion at the time of this writing, is expected to release its quarterly earnings report Nov 03, 2021 – Nov 08, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.3 per share this quarter, however they have predicted annual earnings per share of -$1.16 for 2021 and -$0.74 for 2022. It means analysts are expecting annual earnings per share growth of -6.40% this year and 36.20% next year.
Analysts have forecast the company to bring in revenue of $40.22 million for the current quarter, with the likely lows of $35 million and highs of $49 million. The average estimate suggests sales will likely up by 1,017.20% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2021 is $156.06 million. The company’s revenue is forecast to grow by 776.20% over what it did in 2021.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of BioCryst Pharmaceuticals Inc. No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest BCRX has a Hold on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a Hold, while an average of long term indicators suggests that the stock is currently 50% Buy.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned BCRX a recommendation rating is 12. Out of them, 3 rate it a Hold, while 8 recommend Buy, whereas 1 assign an Overweight rating. 0 analyst(s) have tagged BioCryst Pharmaceuticals Inc. (BCRX) as Underweight, while 0 advise Sell. Analysts have rated the stock Overweight, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that BCRX’s price is currently 0.25% off the SMA20 and -3.75% off the SMA50. The RSI metric on the 14-day chart is currently showing 50.04, and weekly volatility stands at 3.52%. When measured over the past 30 days, the indicator reaches 3.66%. BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)’s beta value is currently sitting at 2.56, while the Average True Range indicator is currently displaying 0.56. With analysts defining $16.00-$30.00 as the low and high price targets, we arrive at a consensus price target of $21.27 for the trailing 12-month period. The current price is about -8.77% off the estimated low and -103.94% off the forecast high, based on this estimate. Investors will be thrilled if BCRX’s share price rises to $21.00, which is the median consensus price. At that level, BCRX’s share price would be -42.76% below current price.
To see how BioCryst Pharmaceuticals Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: BCRX stock’s performance was 2.01% in the latest trading, and 282.57% in the past year, while CEL-SCI Corporation (CVM) has traded 2.41% on the day and positioned -28.24% lower than it was a year ago. Another comparable company Emergent BioSolutions Inc. (EBS) saw its stock close -0.97% lower in the most recent trading session but was down -54.18% in a year. Furthermore, Sarepta Therapeutics Inc. (SRPT) showed an increase of 4.14% on the day while its price kept declining at -33.46% over the past year. BioCryst Pharmaceuticals Inc. has a P/E ratio of 0. Also in last trading session, the S&P 500 Index has plunged -0.24%, while the Dow Jones Industrial also saw a negative session, down -0.34% on the day.
An evaluation of the daily trading volume of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) indicates that the 3-month average is 2.70 million. However, this figure has increased over the past 10 days to an average of 2.21 million.
Currently, records show that 178.13 million of the company’s shares remain outstanding. The insiders hold 0.20% of outstanding shares, whereas institutions hold 59.90%. The stats also highlight that short interest as of Jul 29, 2021, stood at 18.35 million shares, resulting in a short ratio of 7.62 at that time. From this, we can conclude that short interest is 10.26% of the company’s total outstanding shares. It is noteworthy that short shares in July were down slightly from the previous month’s figure, which was 19.15 million. However, since the stock’s price has seen 97.45% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.